CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5502.21M
Enterprise Value 3394.81M
Trailing P/E N/A
Forward P/E 1-5.66
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)559.88
Price/Book (mrq)3.47
Enterprise Value/Revenue 3440.14
Enterprise Value/EBITDA 6-6.51

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-36.69%
S&P500 52-Week Change 35.66%
52 Week High 326.67
52 Week Low 310.63
50-Day Moving Average 317.20
200-Day Moving Average 318.81

Share Statistics

Avg Vol (3 month) 3248.15k
Avg Vol (10 day) 3199.7k
Shares Outstanding 532.85M
Float 16.5M
% Held by Insiders 14.49%
% Held by Institutions 174.70%
Shares Short (Jun. 14, 2020) 41.38M
Short Ratio (Jun. 14, 2020) 47.83
Short % of Float (Jun. 14, 2020) 45.77%
Short % of Shares Outstanding (Jun. 14, 2020) 44.21%
Shares Short (prior month May 14, 2020) 41.34M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020


Profit Margin 0.00%
Operating Margin (ttm)-6,863.99%

Management Effectiveness

Return on Assets (ttm)-26.48%
Return on Equity (ttm)-45.06%

Income Statement

Revenue (ttm)897k
Revenue Per Share (ttm)0.04
Quarterly Revenue Growth (yoy)-80.70%
Gross Profit (ttm)-40.31M
EBITDA -60.65M
Net Income Avi to Common (ttm)-58.77M
Diluted EPS (ttm)-2.42
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)112.8M
Total Cash Per Share (mrq)3.43
Total Debt (mrq)5.4M
Total Debt/Equity (mrq)4.98
Current Ratio (mrq)10.89
Book Value Per Share (mrq)4.41

Cash Flow Statement

Operating Cash Flow (ttm)-51.85M
Levered Free Cash Flow (ttm)-30.9M